NEW YORK (GenomeWeb News) – Abbott said today that it has completed the separation of its research-based pharmaceutical business, which has been spun out into a publicly traded entity called AbbVie.

Abbott announced its plans to split the company into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals — in October 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.